TRCT
INBX icon

Tower Research Capital (TRC)’s Inhibrx INBX Stock Holding History

Tower Research Capital (TRC)’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.3K Buy
1,388
+729
+111% +$54.1K ﹤0.01% 2238
2025
Q4 		$52.1K Sell
659
-384
-37% -$26.2K ﹤0.01% 2393
2025
Q3 		$35.1K Sell
1,043
-1,173
-53% -$28.9K ﹤0.01% 2804
2025
Q2 		$31.6K Buy
2,216
+1,347
+155% +$17.4K ﹤0.01% 3357
2025
Q1 		$12.2K Sell
869
-98
-10% -$1.33K ﹤0.01% 3461
2024
Q4 		$14.9K Buy
967
+74
+8% +$1.13K ﹤0.01% 3438
2024
Q3 		$14K Sell
893
-2,009
-69% -$28.2K ﹤0.01% 3484
2024
Q2 		$41.1K Buy
+2,902
New +$45.3K ﹤0.01% 3240

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Tower Research Capital (TRC)'s INBX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Inhibrx (INBX) stake by 111% in Q1 2026, buying an estimated $54.1K and bringing the position to 1,388 shares worth $93.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Tower Research Capital (TRC) first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Tower Research Capital (TRC) held 1,388 shares of Inhibrx worth $93.3K as of Q1 2026.
  • Tower Research Capital (TRC) bought 729 Inhibrx shares in Q1 2026, an estimated $54.1K.
  • Inhibrx made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2238 holding.
  • Tower Research Capital (TRC) first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.